XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current Assets    
Cash and cash equivalents $ 5,579 $ 6,841
Short-term investments 40 252
Accounts receivable (net of allowance for doubtful accounts of $80 in 2024 and $88 in 2023) 11,366 10,349
Inventories (excludes inventories of $3,413 in 2024 and $3,348 in 2023 classified in Other assets - see Note 6) 6,510 6,358
Other current assets 7,950 8,368
Total current assets 31,445 32,168
Investments 280 252
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,620 in 2024 and $18,266 in 2023 23,045 23,051
Goodwill 21,181 21,197
Other Intangibles, Net 17,572 18,011
Other Assets 12,326 11,996
Total Assets 105,849 106,675
Current Liabilities    
Loans payable and current portion of long-term debt 3,077 1,372
Trade accounts payable 3,514 3,922
Accrued and other current liabilities 14,102 15,766
Income taxes payable 2,398 2,649
Dividends payable 2,008 1,985
Total current liabilities 25,099 25,694
Long-Term Debt 31,142 33,683
Deferred Income Taxes 922 871
Other Noncurrent Liabilities 8,262 8,792
Merck & Co., Inc. Stockholders’ Equity    
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023 1,788 1,788
Other paid-in capital 44,598 44,509
Retained earnings 56,697 53,895
Accumulated other comprehensive loss (5,274) (5,161)
Stockholders' equity before deduction for treasury stock 97,809 95,031
Less treasury stock, at cost: 1,044,402,655 shares in 2024 and 1,045,470,249 shares in 2023 57,445 57,450
Total Merck & Co., Inc. stockholders’ equity 40,364 37,581
Noncontrolling Interests 60 54
Total equity 40,424 37,635
Liabilities and Equity $ 105,849 $ 106,675